Compare CNXU & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXU | SEER |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.7M | 108.0M |
| IPO Year | 2025 | 2020 |
| Metric | CNXU | SEER |
|---|---|---|
| Price | $3.32 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 163.1K | ★ 211.8K |
| Earning Date | 02-03-2027 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $3.60 | $1.55 |
| 52 Week High | $13.66 | $2.41 |
| Indicator | CNXU | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 29.51 | 66.80 |
| Support Level | N/A | $1.81 |
| Resistance Level | $5.47 | $2.24 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 2.97 | 81.63 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.